 BOSTON, MA ACCESSWIRE September 8, 2022 Pieris Pharmaceuticals, Inc. NASDAQ:PIRS , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 12:30 PM EDT. 